Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$8.6M
Filings
183
Firms Hired
4
Active Period
2008–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 1227
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: HR 5526
Consolidated Appropriations Act, 2026
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 7148
Consolidated Appropriations Act, 2026
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 7148
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 8143
Lower Costs, More Transparency Act of 2026
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: H.R.9393
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: S. 1954
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: S. 2355
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: S. 3822
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 1227
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: HR 5526
Consolidated Appropriations Act, 2026
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 7148
Consolidated Appropriations Act, 2026
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 7148
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 8143
Lower Costs, More Transparency Act of 2026
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: H.R.9393
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: S. 1954
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: S. 2355
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $140,000 · Firm income: —
Matched citations: S. 3822
Patients Deserve Price Tags Act
2026 · second_quarter · Firm: GOVERNMENT COUNSEL, LLC
Consolidated Appropriations Act(CAA)of 2026 (P.L. 119-75); S. 2355-Patients Deserve Price Tag Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 2355
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 1227
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $100,000 · Firm income: —
Matched citations: HR 5526
Consolidated Appropriations Act, 2026
2026 · second_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 7148
Consolidated Appropriations Act, 2026
2026 · second_quarter · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 7148
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
2026 · second_quarter · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 8143
Lower Costs, More Transparency Act of 2026
2026 · second_quarter · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
Client expense: $100,000 · Firm income: —
Matched citations: H.R.9393
Source: Senate LDA